Peregrine Pharmaceuticals (PPHM) Reports In-Line Q4 EPS

Peregrine Pharmaceuticals (NASDAQ: PPHM) reported Q4 EPS of ($0.06), in-line with the analyst estimate of ($0.06). Revenue for the quarter came in at $4.25 million versus the consensus estimate of $3.57 million.

For earnings history and earnings-related data on Peregrine Pharmaceuticals (PPHM) click here.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Rivian reports record Q3 deliveries, beats estimates, shares rise
• Onto Innovation gains on bullish RBC initiation citing advanced packaging growth
• Rivian reports Q3 2026 production of 19,751 vehicles